Welcome to our dedicated page for Gt Biopharma SEC filings (Ticker: GTBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GT Biopharma Inc. (GTBP) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission documents, including registration statements, current reports, and other disclosures related to its clinical-stage immuno-oncology business. As a Nasdaq Capital Market issuer and smaller reporting company, GT Biopharma files detailed information on its TriKE natural killer (NK) cell engager platform, capital structure, and risk factors.
Key filings include S-1 and S-1/A registration statements that describe the company’s focus on developing and commercializing novel immuno-oncology products based on its TriKE and Tetra-specific Killer Engager constructs. These documents outline offerings of common stock by selling stockholders, shares issuable upon conversion of Series L 10% Convertible Preferred Stock, warrants, and pre-funded warrants, as well as a common shares purchase agreement that allows the company to sell additional shares to certain investors.
Current reports on Form 8-K provide timely updates on material events. For GT Biopharma, these include notices from Nasdaq regarding minimum bid price compliance, waivers by Series L preferred stockholders of certain redemption rights, amendments to executive employment agreements, annual meeting voting results, and the furnishing of quarterly financial press releases. Several 8-K filings also explain that, effective July 1, 2024, the company became fully remote and does not maintain a principal executive office, while specifying how stockholder communications may be directed for regulatory purposes.
Through this page, users can review GTBP’s 10-K and 10-Q reports (when filed), which incorporate financial statements, management’s discussion and analysis, and extensive risk factor sections referenced in the S-1 and S-1/A prospectuses. Form 4 insider transaction reports, when available, offer insight into equity transactions by directors and officers.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, such as changes in capital structure, clinical development disclosures for GTB-3650 and GTB-5550, and updates on liquidity and operating plans. Real-time EDGAR updates help ensure new GTBP filings appear quickly, while AI-generated explanations aim to make complex registration statements, 8-Ks, and future 10-K or 10-Q reports more understandable for investors reviewing GT Biopharma’s regulatory history.
GT Biopharma, Inc. (Nasdaq: GTBP) has filed Amendment No. 1 to its Form S-1 shelf registration statement dated 27 June 2025. The filing registers up to 54,423,826 shares of common stock for resale by several selling stockholders. GT Biopharma will not receive proceeds from the resale of these shares, though it could receive cash upon the initial issuance of certain securities (e.g., warrant exercises or sales under a committed equity facility).
Share-count breakdown
- 14,561,913 shares issuable on conversion of 6,612 shares of Series L 10% Convertible Preferred Stock issued in a May 2025 private placement.
- 14,561,913 shares issuable upon exercise of related common stock warrants.
- 300,000 commitment shares issuable on exercise of pre-funded warrants issued to Bristol Capital, LLC and Five Narrow Lane, L.P.
- Up to 25,000,000 shares issuable and resellable by the Facility Investors (Five Narrow Lane, L.P. and Hailstone Peak Funding, LLC) under a committed equity facility (CEF) established on 14 May 2025.
The company has agreed to bear registration expenses; selling stockholders will cover brokerage or underwriting costs. The registration gives stockholders the flexibility to dispose of shares “from time to time” using various methods outlined under “Plan of Distribution.”
Corporate and filing status
- State of incorporation: Delaware.
- Filer status: Non-accelerated filer & Smaller Reporting Company.
- GTBP became a fully remote company effective 1 July 2024 and lists a mailing address at 505 Montgomery St., San Francisco.
- Nasdaq Capital Market ticker: GTBP; closing price on 26 June 2025 was $3.80.
Key investor considerations
- The potential issuance of 54.4 million shares represents meaningful dilution relative to current outstanding shares and may exert downward pressure on the share price.
- While no resale proceeds flow to GTBP, the committed equity facility (up to 25 million shares) could provide future funding when shares are initially sold to the Facility Investors.
- The prospectus directs investors to the “Risk Factors” section (page 7) for a detailed discussion of material risks associated with the securities.